Grigoris Grimbizis

Grigoris Grimbizis

Auto-generated profile, based on publicly available information

Grigoris Grimbizis

1st Department of Obstetrics & Gynecology, Aristotle University of Thessaloniki, “Papageorgiou” Hospital, 56403 Thessaloniki, Greece

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 June 2025 in Cancers
Verified
Journal Article
Open access
PDF file
DZDimitrios Zouzoulas
Dimitrios Zouzoulas
TKTilemachos Karalis
Tilemachos Karalis
ISIliana Sofianou
Iliana Sofianou
CAChristos Anthoulakis
Christos Anthoulakis
ATAikaterini Tzika
Aikaterini Tzika
DTDimitrios Tsolakidis
Dimitrios Tsolakidis
Background/Objectives: Ovarian and endometrial cancers present significant health burdens due to their substantial morbidity and mortality. Surgery delay is hypothesized to negatively impact patient outcomes, yet evidence remains inconsistent. This systematic review aims to comprehensively evaluate current evidence regarding the effects of treatment delay on survival and quality of life in these patients. Methods: A systematic literature search was conducted in MEDLINE (PubMed), Cochrane Library, Scopus, and ClinicalTrials.gov databases, complemented by a manual screening of reference lists, with studies included up to March 2025. Two independent reviewers screened and assessed the methodological quality using the ROBINS-E tool and extracted the data from the studies. Due to substantial methodological and clinical heterogeneity, results were synthesized qualitatively through narrative synthesis. Results: Twenty-one studies met the inclusion criteria, comprising predominantly retrospective cohort analyses. Treatment delays consistently correlated with decreased survival and advanced disease stages. Among studies, optimal intervals from diagnosis to treatment were varied from 2 to 8 weeks. Patient-reported outcomes indicated heightened anxiety, increased distress, and poor satisfaction with prolonged delays. Healthcare system factors such as resource allocation, geographic disparities, and socioeconomic inequalities significantly contributed to delays. Quantitative survival metrics supported a clear negative association between treatment delays and survival, although paradoxical outcomes in select subgroups highlighted underlying complexities. Conclusions: This systematic review underscores the critical importance of minimizing delays in the treatment of ovarian and endometrial cancers to improve patient survival and psychological outcomes. Identified healthcare system barriers demand targeted policy interventions to ensure timely and equitable access to tertiary healthcare infrastructures. Future research should prioritize standardizing delay definitions to strengthen and homogenize evidence.

24 March 2024 in Cancers
Verified
Journal Article
Open access
PDF file
DZDimitrios Zouzoulas
Dimitrios Zouzoulas
DTDimitrios Tsolakidis
Dimitrios Tsolakidis
PTPanagiotis Tzitzis
Panagiotis Tzitzis
ISILIANA SOFIANOU
ILIANA SOFIANOU
KCKimon Chatzistamatiou
Kimon Chatzistamatiou
GGGrigoris Grimbizis
Grigoris Grimbizis
(1) Background: Neoadjuvant chemotherapy followed by interval debulking surgery is used in the treatment of advanced ovarian cancer. However, no tool can safely predict if complete cytoreduction after 3–4 cycles can be achieved. This study aims to investigate if the KELIM score can be a triage tool in the identification of patients that will be ideal candidates for interval debulking surgery (IDS). (2) Methods: We retrospectively analyzed the records of patients with high-grade serous advanced ovarian cancer that were treated in the 1st Department of Obstetrics–Gynecology, 2012–2022, with neoadjuvant chemotherapy followed by IDS. Patient characteristics, oncological outcome and follow-up information were collected. The primary outcome was the association of the KELIM score with residual disease. (3) Results: 83 patients were categorized into two groups: Group A (51 patients) with favorable (≥1) and Group B (32 patients) with unfavorable (<1) KELIM scores. A statistically significant correlation between KELIM and residual disease (p < 0.05) exists, showing that patients with a favorable KELIM score can achieve a complete IDS. Furthermore, there was a statistically significant difference in overall survival (p = 0.017), but no difference was observed in progression-free survival (p = 0.13); (4) Conclusions: KELIM seems to safely triage patients after neoadjuvant chemotherapy and decide who will benefit from IDS.

18 April 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
PIPinelopi Ioannidou
Pinelopi Ioannidou
TZTheodosia Zeginiadou
Theodosia Zeginiadou
CVChristos Venetis
Christos Venetis
DPDimitrios Papanikolaou
Dimitrios Papanikolaou
LZLeonidas Zepiridis
Leonidas Zepiridis
EKEfstratios Kolibianakis
Efstratios Kolibianakis
A randomized, placebo-controlled, quadruple-blind trial was performed to evaluate the effect of oral administration of the antioxidant combination Spermotrend® for three months on semen quality in infertile men with at least one abnormal variable in semen analysis. Eighty men were randomized between 2019 and 2022, receiving either the antioxidant combination Spermotrend® (n = 40, spermotrend-group) or placebo (n = 40, placebo-group). Although a total of 80 patients were enrolled in the study, the final data is only from 70 patients. The primary outcome measure was sperm motility (rapid progressive, progressive, and total motility). The values of primary and secondary outcomes between treatment initiation and treatment completion were compared within groups. Moreover, their changes between treatment initiation and treatment completion were compared between the placebo- and the spermotrend-groups. Sperm rapid progressive motility significantly increased in infertile men treated for three months with antioxidant combination Spermotrend® (+1.0%, 95% CI: 0.0 to +2.0, p = 0.04), while this increase was not observed in the placebo-group. Sperm progressive motility significantly increased in infertile men treated for three months with antioxidant combination Spermotrend® (+3.0%, 95% CI: 0.0 to +15.1, p = 0.02), while this increase was not observed in the placebo-group. Similarly, DFI was significantly decreased in infertile men treated for three months by antioxidant combination Spermotrend® (−3.2%, 95% CI: −5.8 to −0.5, p = 0.02). However, no statistically significant differences were observed in the changes of pre- and post-treatment values between the spermotrend- and the placebo-group regarding sperm progressive motility, concentration, normal morphology, DFI, and formation of 8-OH-dG. The antioxidant combination Spermotrend® appears to exert limited benefit on sperm motility and DFI in infertile men with at least one abnormal variable in semen analysis.

22 January 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DZDimitrios Zouzoulas
Dimitrios Zouzoulas
ISIliana Sofianou
Iliana Sofianou
EMEfthalia Markopoulou
Efthalia Markopoulou
TKTilemachos Karalis
Tilemachos Karalis
KCKimon Chatzistamatiou
Kimon Chatzistamatiou
DTDimitrios Tsolakidis
Dimitrios Tsolakidis
(1) Background: Advance-stage endometrial cancer is a rare disease that encompasses a heterogeneous group of patients. Primary surgery is the treatment of choice, while neoadjuvant chemotherapy (NACT) seems to be an alternative option for inoperable frail patients. The aim of this study was to identify possible prognostic factors for advance-stage endometrial cancer patients. (2) Methods: We retrospectively analyzed the records of patients with endometrial cancer that underwent surgery in the 1st Department of Obstetrics–Gynecology from 2012 to 2023. Patients with advance-stage disease (FIGO stage III–IV) were included, while those with incidental microscopic lymph node metastases after staging lymphadenectomy were excluded. (3) Results: The population of this study consisted of 89 women. Patients were obese, with moderate comorbidities and a median age of 64 years old. The majority of them (75.3%) had FIGO stage IIIC disease, while one-fourth (24.7%) presented with peritoneal metastases (FIGO stage IV). Most patients had endometrioid, high-grade tumors, with substantial lymphovascular space invasion (LVSI) and deep myometrial invasion. Complete gross resection was achieved in 92.1% of the patients. NACT was administrated in 14.6% of the population. Deep myometrial invasion and non-endometrioid histology were recognized as independent prognostic factors for worse PFS, but no association was found for OS. Concerning survival rates, the median progression-free (PFS) and overall (OS) survival were 44 and 70 months, respectively. (4) Conclusions: Myometrial invasion and histological subtypes seem to affect the recurrence rate of advanced endometrial cancer patients. NACT could likely be an alternative for primarily inoperable and frail patients, but does not appear to alter survival rates.

5 February 2026 in Cancers
Verified
Journal Article
Open access
PDF file
DZDimitrios Zouzoulas
Dimitrios Zouzoulas
PTPanagiotis Tzitzis
Panagiotis Tzitzis
ISIliana Sofianou
Iliana Sofianou
ATAikaterini Tzika
Aikaterini Tzika
KCKimon Chatzistamatiou
Kimon Chatzistamatiou
DTDimitrios Tsolakidis
Dimitrios Tsolakidis
(1) Background: Hudson first described the procedure that includes en-block removal of an ovarian tumor fixed in the pelvis with the whole pelvic peritoneum and invaded surrounding structures. However, sometimes pelvic peritonectomy (PP) with or without shaving of the bowel serosa is not enough to achieve complete cytoreduction, and en-block rectosigmoid resection (RR) is necessary. This study aims to investigate the impact of bowel surgery on survival rates and morbidity of patients with advanced ovarian cancer. (2) Methods: We retrospectively analyzed patients with advanced ovarian cancer with cul-de-sac involvement that underwent debulking surgery at the 1st Department of Obstetrics—Gynecology of “Papageorgiou” General Hospital, from 2017–2022. The primary outcomes were the survival rates and morbidity between PP and RR. (3) Results: A total of 93 patients met the inclusion criteria. Patients were categorized into two groups: Group A (34 patients) with RR and Group B (59 patients) with PP. There was no statistically significant difference in the majority of patients’ characteristics and oncological outcomes. On the other hand, patients with RR had a significantly higher surgical complexity score (SCS), peritoneal cancer index (PCI), ICU admission, rate of postoperative complications, longer surgery duration and hospital stay. When comparing the duration of surgery, the RR group has significantly higher operation time during primary compared to interval debulking surgery. Concerning survival rates, there was no significant difference in progression-free (PFS) (p = 0.22) and overall survival (OS) (p = 0.85) between the two groups, while residual disease and postoperative complications were identified as independent prognostic factors for PFS and OS; (4) Conclusions: The modified Hudson procedure with RR is a safe and reproductible technique, but when complete gross resection can be achieved with PP, this technique is preferred in order to avoid increased patient’s morbidity.

3 March 2026 in Medical Sciences
Verified
Journal Article
Open access
PDF file
DZDimitrios Zouzoulas
Dimitrios Zouzoulas
TKTilemachos Karalis
Tilemachos Karalis
ISILIANA SOFIANOU
ILIANA SOFIANOU
PTPanagiotis Tzitzis
Panagiotis Tzitzis
TMThemistoklis Mikos
Themistoklis Mikos
DTDimitrios Tsolakidis
Dimitrios Tsolakidis
Background/Objectives: Pregnancy-associated breast cancer (PABC) is uncommon but increasingly encountered as more women delay childbearing. Its prognostic impact remains controversial, particularly for cancers diagnosed in the early postpartum period. We aimed to synthesize contemporary evidence on the prognosis of breast cancer diagnosed during pregnancy or within 12 months after delivery compared with breast cancer in other young women, with a specific focus on differences between pregnancy time and postpartum disease. Methods: We performed a systematic review of observational studies published from 2005 onwards that reported oncologic outcomes for women with invasive PABC versus non-PABC comparators or PABC-only cohorts with internal timing comparisons. PubMed, Cochrane Library, Scopus and ClinicalTrials.gov were systematically searched using predefined strategies. Two reviewers independently screened records, extracted data and assessed risk of bias using the ROBINS-E tool, treating PABC status as the exposure. Because of substantial heterogeneity in PABC definitions, outcomes and adjustment sets, no meta-analysis was performed. Results: Twenty-one observational studies (single-center, multicenter and population-based) were included. PABC cases more often presented with larger tumors, higher nodal burden, high-grade and hormone receptor-negative/HER2-positive phenotypes and worse survival compared to non-PABC controls. In most contemporary cohorts that delivered guideline-oriented therapy and adjusted for stage and tumor biology, a diagnosis during pregnancy was not an independent predictor of poorer disease-free or overall survival. In contrast, multiple large registry and institutional studies reported significantly higher risks of recurrence and death for cancers diagnosed in the early postpartum period, even after multivariable adjustment. Conclusions: Current evidence suggests that pregnancy itself does not inevitably worsen breast cancer prognosis when treatment is not compromised. However, breast cancers diagnosed soon after childbirth represent a distinct high-risk subgroup. These findings support full-intensity, guideline-based therapy during pregnancy and highlight the need for special attention and further research focused on postpartum breast cancer.